Managed Account Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Managed Account Advisors’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$310K	Buy	+2,042	New	+$337K	﹤0.01%	2395

Other funds holding KDNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

M&T Bank Buffalo, New York $29.2B AUM 22.81% 1-Year Est. Return

CCP

Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Managed Account Advisors's KDNY Position: Q2 2015 in Review

Managed Account Advisors opened a new position in Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2015: 2,042 shares worth $310K. The stake represents ﹤0.01% of the portfolio and ranks #2395 among its holdings.

80 funds tracked by Wall St. Rank hold KDNY as of Q2 2015.

Managed Account Advisors held 2,042 shares of Chinook Therapeutics, Inc. Common Stock worth $310K as of Q2 2015.
Chinook Therapeutics, Inc. Common Stock was a new Managed Account Advisors position in Q2 2015.
Chinook Therapeutics, Inc. Common Stock made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #2395 holding.
80 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.